secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001104659-24-010337
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco sells aqua business to Merck Animal Health for $1.3B cash
----------------------------------------------------------------

- Transaction valued at approx. 7.4x estimated 2023 revenue of $175M and adjusted EBITDA of $92M.
- After-tax proceeds of $1.05B-$1.1B to be used to pay down Term Loan B debt, reducing interest expense ~$65M annually.
- Pro forma net leverage ratio would have been ~5.0x for 2023, down from slight below midpoint of 5.5x-5.8x guidance.
- Expected close around mid-2024, subject to regulatory approvals and customary conditions.
- Divestiture includes ~280 employees, manufacturing sites in Canada and Vietnam, and R&D projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924010337/0001104659-24-010337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924010337/tm245182d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer